List of voters for the quote

The first trial in the programme is planned for initiation in first quarter of 2016 and will investigate the efficacy and safety of once-daily oral semaglutide doses of 3 mg, 7 mg and 14 mg, compared to once-daily oral anti-diabetic sitagliptin dose of 100 mg, the remaining six trials of the PIONEER programme are all expected to be initiated during 2016.

This page is about the voters of this citizen quote.